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Abstract
Background: Gestational diabetes mellitus (GDM) is associated with adverse pregnancy outcomes. It is known that
GDM is associated with an altered placental function and changes in placental gene regulation. More recent studies
demonstrated an involvement of epigenetic mechanisms. So far, the focus regarding placental epigenetic changes
in GDM was set on gene-specific DNA methylation analyses. Studies that robustly investigated placental global DNA
methylation are lacking. However, several studies showed that tissue-specific alterations in global DNA methylation
are independently associated with type 2 diabetes. Thus, the aim of this study was to characterize global placental
DNA methylation by robustly measuring placental DNA 5-methylcytosine (5mC) content and to examine whether
differences in placental global DNA methylation are associated with GDM.
Methods: Global DNA methylation was quantified by the current gold standard method, LC-MS/MS. In total, 1030
placental samples were analyzed in this single-center birth cohort study.
Results: Mothers with GDM displayed a significantly increased global placental DNA methylation (3.22 ± 0.63 vs.
3.00 ± 0.46 %; p = 0.013; ±SD). Bivariate logistic regression showed a highly significant positive correlation between
global placental DNA methylation and the presence of GDM (p = 0.0009). Quintile stratification according to placental
DNA 5mC levels revealed that the frequency of GDM was evenly distributed in quintiles 1–4 (2.9–5.3 %), whereas the
frequency in the fifth quintile was significantly higher (10.7 %; p = 0.003). Bivariate logistic models adjusted for maternal
age, BMI, ethnicity, recurrent miscarriages, and familiar diabetes predisposition clearly demonstrated an independent
association between global placental DNA hypermethylation and GDM. Furthermore, an ANCOVA model considering
known predictors of DNA methylation substantiated an independent association between GDM and placental
DNA methylation.
Conclusions: This is the first study that employed a robust quantitative assessment of placental global DNA
methylation in over a thousand placental samples. The study provides large scale evidence that placental global
DNA hypermethylation is associated with GDM, independent of established risk factors.
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Background
Gestational diabetes mellitus (GDM) is defined as any
degree of glucose intolerance with a first recognition
during pregnancy [1]. In population based studies, the
prevalence of GDM varies from 1 to 14 % with higher
occurrences in specific populations [1, 2]. Ethnic dispar-
ities are existing, with Asians having the highest rate of
GDM, followed by Hispanics, African Americans, and
Caucasians [1]. GDM is associated with a markedly in-
creased risk of adverse pregnancy outcome for both
mother and infant. Mothers suffering from GDM have a
higher risk for preeclampsia and cesarean delivery [3–5].
GDM pregnancies are associated with an increased
perinatal morbidity and mortality, with an elevated risk
for malformations, substantially higher rates of prema-
ture birth and neonatal hypoglycemia [3–5]. Newborns
of pregnancies complicated by GDM show an increased
risk to display altered growth patterns with increased
neonatal body fat and a higher birth weight and
ponderal index [3–5]. Evidence is accumulating that the
intrauterine exposure to GDM also might contribute to
long-lasting effects on the offspring by metabolic
programming, leading to a higher disease susceptibility
later in life [1]. Risk factors for GDM include age, a pre-
pregnancy body mass index (BMI) >25.0 kg/m2, ethnic
background, a history of GDM in previous pregnancies,
glucosuria, a strong first-degree family history of type 2
diabetes or GDM, and a history of unexplained stillbirth
or recurrent miscarriages [6, 7]. The placenta is the pri-
mary means of communication between mother and
fetus and a target for maternal and/or fetal metabolic
disturbances associated with GDM. Placentas of diabetic
pregnancies show an increased placental to fetal ratio
and are characterized by pathohistological findings [8].
The increased risk for adverse pregnancy outcome in
GDM may be associated with these placental structural
and functional changes. The molecular pathways behind
this are incompletely understood so far. It is known that
GDM is associated with altered placental gene regula-
tion, and there is data indicating an involvement of
epigenetic mechanisms [9–13]. So far, the focus regard-
ing placental epigenetic changes in GDM was predomin-
antly set on gene specific DNA methylation [10–13].
There are several studies that applied genome wide ap-
proaches, using the Illumina Infinium 450K BeadChips
assay that measures CpG island methylation in about
99 % of all RefSeq genes [11–13]. However, such arrays
only cover about 1.5 % of overall genomic CpGs, are
biased towards the measurement of promoter methyla-
tion, and neglect other regions and functions of DNA
methylation, thus cannot be regarded as a method to
measure global DNA methylation [14, 15]. Furthermore,
only about 1.5 % of the total genome sequence is
comprised of protein encoding genes, while the remaining
majority encompasses introns, repetitive elements, and
other non-coding sequences [16]. Recent research has
demonstrated important functions of DNA methylation
in such non-coding genomic regions [14, 15, 17–19].
Although various sequencing methods are available for
a detailed, site-specific analysis of global DNA methyla-
tion, these methods are very costly and time consuming,
rendering them impracticable for DNA methylation ana-
lysis of large sample sizes [20]. Previous studies have
demonstrated that the placenta is characterized by global
DNA hypomethylation, usually a hallmark of various can-
cers. Next to global DNA hypomethylation, the placenta
shares many features found in metastatic tumors, in-
cluding rapid proliferation, invasiveness, and angiogenesis
[21]. It was hypothesized that global DNA hypomethyla-
tion might support the unique functions of this organ
[21–23]. Accordingly, alterations in the degree of global
DNA methylation might be associated with altered pla-
cental function and disease. Until now, there are no large
scale clinical studies that characterized global placental
DNA methylation, assessed by an absolute quantification
of the genomic 5-methylcytosine (5mC) content, in
healthy and GDM afflicted pregnancies [24]. Thus, the
aim of this study was to analyze global DNA methylation
in over a thousand placental samples by the current
gold standard method, LC-MS/MS, to truly asses the
degree of global placental DNA methylation in uncom-
plicated pregnancies and to investigate whether GDM
is associated with alterations in global placental DNA
methylation.
Results
Table 1 displays detailed descriptive statistics of the
1030 mothers and their newborns and descriptive sta-
tistics of the study population grouped according to the
presence or absence of GDM. Considering that patient
recruitment was performed at a university clinic, the
cohort did not display any uncommon features. The
mean age of the mothers was 30.0 ± 5.9 years, and the
mean BMI before pregnancy was 23.1 ± 4.5 kg/m2;
93.5 % of all mothers were of Caucasian, 0.9 % of
African, 3.7 % of Asian, and 1.9 % of other ethnic back-
ground. Of all mothers, 5.4 % developed diabetes
during pregnancy. The overall mean degree of placental
DNA methylation was 3.01 ± 0.48 %. Data were nor-
mally distributed. Also shown in Table 1 are detailed
descriptive statistics of the study population grouped
according to the presence of GDM (n = 56) or no GDM
(n = 974). Mothers with GDM had a significantly higher
degree of placental global DNA methylation (3.22 ± 0.63
vs. 3.00 ± 0.46 %; p = 0.013; ±SD, Fig. 1), were older (31.9
± 5.1 vs. 29.8 ± 5.9 years; p = 0.011; ±SD), and had higher
HbA1c concentrations (58 ± 3.3 vs. 42 ± 6.6 mmol/mol;
p < 0.0001; ±SD) and a significantly elevated BMI at
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the beginning and in the third trimester of pregnancy
(24.8 ± 5.8 vs. 23.0 ± 4.4 kg/m2; p = 0.027; 29.6 ± 5.3 vs.
27.5 ± 4.4 kg/m2; p = 0.005). Newborns of GDM mothers
had a significantly increased birth weight (3509.6 ± 742.5
vs. 3329.8 ± 627.1 g; p = 0.039), had an increased pon-
deral index (26.5 ± 3.0 vs. 25.4 ± 2.5; p = 0.002), and
were more often delivered by c-section (40.0 vs 24.4 %;
p = 0.030). Furthermore, the distribution of appropriate
(AGA), small (SGA), and large (LGA) for gestational
age newborns was significantly shifted towards a higher
prevalence of LGA births in GDM mothers (62.5 %
AGA/14.3 % SGA/23.2 % LGA vs. 78.6 % AGA/12.9 %
SGA/8.6 % LGA; p = 0.001;). LGA was also associated
with significantly increased placental DNA methylation
(3.19 ± 0.55 %) compared to SGA (3.01 ± 0.43 %; p < 0.01)
and AGA (2.99 ± 0.47 %; p < 0.001).
Bivariate logistic regression showed a highly significant
correlation between placental DNA methylation and pres-
ence of GDM in an unadjusted model (Exp(B): 2.373; 95 %
CI 1.425–3.954; p = 0.0009). To further categorize this rela-
tionship, quintiles of placental DNA methylation were gen-
erated (five groups of n = 206) and analyzed in crosstabs for
the frequency distribution of gestational diabetes. Figure 2
shows a cross tabulation of placental DNA methylation
ranked in quintiles and the occurrence of GDM. The fre-
quency of GDM was evenly distributed in quintiles 1–4
with frequencies ranging between 2.9 and 5.3 %, only in the
fifth quintile a significantly higher GDM frequency of
10.7 % was found (Pearson chi square 16.127; p = 0.003;
Fig. 2). This observation was even more significant after re-
stratification into two groups, the first consisting of pla-
cental DNA methylation quintiles 1–4 (n = 824) and the
Table 1 Descriptive data of all mother/child pairs and grouped according to GDM
Maternal characteristics All mothers
(n = 1030)
Presence of GDM
No GDM (n = 974) GDM (n = 56) p valuea
Maternal age, years 30.0 ± 5.9 29.8 ± 5.9 31.9 ± 5.1 0.011
Ethnicity (Caucasian, non-Caucasian), % 93.5/6.5 93.5/6.5 92.9/7.1 0.842
Maternal height, cm 166.9 ± 7.0 167.0 ± 6.9 166.4 ± 8.4 0.637
Body mass index before pregnancy, kg/m2 23.1 ± 4.5 23.0 ± 4.4 24.8 ± 5.8 0.027
Body mass index 3rd trimester, kg/m2 27.6 ± 4.5 27.5 ± 4.4 29.6 ± 5.3 0.005
Hypertension before/during pregnancy, % 2.3/3.8 2.3/3.6 1.8/7.1 0.809/0.331
Diabetes mellitus before/during pregnancy, % 0.0/5.4 0.0/0.0 0.0/100.0 –
Diabetes in family, % 38.1 37.7 44.6 0.300
Mean systolic blood pressure 3rd trimester, mmHg 116.2 ± 11.1 116.3 ± 11.1 114.1 ± 10.9 0.159
Mean diastolic blood pressure 3rd trimester, mmHg 70.3 ± 7.5 70.4 ± 7.5 69.4 ± 8.4 0.345
Smoking before/during pregnancy, % 35.3/13.6 35.5/13.7 32.1/12.5 0.613/0.801
Placental DNA methylation, % 3.01 ± 0.48 3.00 ± 0.46 3.22 ± 0.63 0.013
Parity number ≤1/≥2, % 75.7/24.3 75.9/24.1 72.2/27.8 0.545
s/p 2 or more miscarriages, % 6.5 6.4 8.9 0.449
Twin gestations, % 2.1 2.1 3.6 0.445
Gestational age at delivery, weeks 38.7 ± 2.1 38.7 ± 2.1 38.4 ± 1.8 0.056
Preterm birth (<37 weeks), % 10.3 10.4 8.9 0.728
Birth weight, g 3339.6 ± 634.8 3329.8 ± 627.1 3509.6 ± 742.5 0.039
AGA/SGA/LGA, % 77.7/13.0/9.4 78.6/12.9/8.6 62.5/14.3/23.2 0.001
Birth length, cm 50.6 ± 3.2 50.6 ± 3.1 50.3 ± 5.0 0.626
Child head circumference, cm 34.7 ± 1.7 34.7 ± 1.7 34.6 ± 1.8 0.719
Ponderal index, kg/m3 25.5 ± 2.5 25.4 ± 2.5 26.5 ± 3.0 0.002
Mode of delivery (spontaneous, OVD, c-section; %) 67.1/7.4/25.5 67.9/7.7/24.4 56.4/3.6/40.0 0.030
Child sex, male/female, % 51.7/48.3 51.6/48.4 53.6/46.4 0.780
Apgar score at 5 min 9.3 ± 1.0 9.3 ± 1.0 9.3 ± 0.9 0.996
Apgar score at 10 min 9.6 ± 0.8 9.6 ± 0.8 9.5 ± 0.7 0.137
Maternal HbA1c, % 6.1 ± 0.7 58 ± 3.3 42 ± 6.6 <0.0001
Data are given as mean ± SD or percentage
aComparison between “GDM” and “no GDM”
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second of methylation quintile 5 (n = 206) (Pearson chi-
square 13.766; p = 0.0002; Table 2).
Table 2 shows detailed descriptive statistics of the study
population according to the abovementioned stratification
into lower degrees of placental DNA methylation (quintiles
1–4; n = 824) versus high placental DNA methylation
(quintile 5; n = 206). There were significant differences
regarding the ethnic composition of the highest methyla-
tion group vs. methylation quintiles 1–4, with more non-
Caucasians in the highest methylation group (9.7 vs. 5.7 %;
p = 0.037). There was a significantly higher frequency of
GDM in the highest methylation group (10.7 vs. 4.1 %; p =
0.0002). Moreover, a significant increase of LGA births was
observed in the highest methylation group (73.0 % AGA,
12.7 % SGA, 14.2 % LGA vs. 78.8 % AGA, 13.0 % SGA,
8.2 % LGA; p = 0.028). Additionally, the Apgar score
10 min postnatally was significantly reduced in the highest
methylation group (9.5 ± 0.8 vs. 9.6 ± 0.7; p = 0.011).
Adjusted bivariate logistic regression models
To demonstrate that a high degree of placental DNA
methylation is independently associated with GDM,
Fig. 1 Box and whiskers plot displaying the mean global placental DNA 5mC content, according to the presence or absence of GDM. Mothers with
GDM had significantly higher mean levels (3.00 %; min 2.02 %; max 4.84 %) of 5mC than mothers without GDM (3.22 %; min 2.03 % max 4.73 %);
#: p=0.013
Fig. 2 Crosstabulation of GDM and placental DNA methylation ranked in quintiles. Ranges of placental DNA 5mC are depicted on
top each respective quintile as box and whisker plots (mean; min; max)
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adjusted bivariate logistic regression models were calcu-
lated. To account for confounding, the models were ad-
justed for available parameters known to be risk factors for
GDM [6]. Risk factors included in the models were mater-
nal age, BMI at the beginning of pregnancy, a history of re-
current (≥2) miscarriages (yes; no), ethnic background
(Caucasian; non-Caucasian), and family history of type 2
diabetes (yes; no). Model A used these confounders to-
gether with placental DNA methylation as a continuous
variable. In this model, placental DNA methylation was sig-
nificantly associated with the presence of GDM ((exp)B =
2.408; 95 % CI 1.427–4.063; p = 0.001; Table 3). In model B,
placental DNA methylation stratified into the before men-
tioned two groups of high placental DNA methylation
(quintile 5; n = 206) and lower degrees of placental DNA
methylation (quintiles 1–4; n = 824) was used. Grouped pla-
cental DNA methylation was associated with the presence
of GDM even more significantly ((exp)B = 2.999; 95 %
CI 1.691–5.316; p = 0.0002; Table 3).
Adjusted ANCOVA model
To demonstrate that GDM is independently associated
with global placental DNA methylation, an ANCOVA
model was calculated and adjusted for predictors of
DNA methylation evinced in previous methylation stu-
dies [25, 26]. These factors included smoking status be-
fore pregnancy (yes/no), ethnic background (Caucasian;
non-Caucasian), sex of the child (male/female), and age
Table 2 Descriptive data of the mother/child pairs grouped according to the degree of placental DNA methylation
Maternal characteristics Degree of placental DNA methylation
Quintiles 1–4 Quintile 5 p valuea
(n = 824) (n = 206)
Maternal age, years 29.9 ± 6.0 30.3 ± 5.5 0.407
Ethnicity (Caucasian, non-Caucasian), % 94.3/5.7 90.3/9.7 0.037
Maternal height, cm 167.0 ± 6.9 166.5 ± 7.3 0.365
Body mass index before pregnancy, kg/m2 23.2 ± 4.5 22.8 ± 4.4 0.094
Body mass index 3rd trimester, kg/m2 27.6 ± 4.5 27.4 ± 4.3 0.801
Hypertension before/during pregnancy, % 2.0/3.5 3.4/4.9 0.200/0.443
Diabetes mellitus during pregnancy, % 4.1 10.7 0.0002
Diabetes in family, % 38.1 38.2 0.964
Mean systolic blood pressure 3rd trimester, mmHg 116.4 ± 11.0 115.3 ± 11.5 0.202
Mean diastolic blood pressure 3rd trimester, mmHg 70.4 ± 7.5 70.0 ± 7.5 0.491
Smoking before/during pregnancy, % 35.4/13.3 34.6/14.7 0.828/0.635
Placental DNA methylation, % 2.84 ± 0.32 3.71 ± 0.34 <0.0001
Parity number <2/≥2, % 76.1/23.9 73.8/26.2 0.481
s/p 2 or more miscarriages, % 6.3 7.3 0.613
twin gestations, % 1.8 3.4 0.161
Gestational age at delivery, weeks 38.7 ± 2.1 38.8 ± 1.8 0.989
Preterm birth (<37 weeks), % 10.3 10.3 0.983
Birth weight, g 3334.8 ± 628.3 3358.5 ± 661.4 0.634
AGA/SGA/LGA, % 78.8/13.0/8.2 73.0/12.7/14.2 0.028
Birth lenght, cm 50.6 ± 3.1 50.5 ± 3.6 0.951
Child head circumference, cm 34.7 ± 1.7 34.6 ± 1.7 0.436
Ponderal index, kg/m3 25.5 ± 2.5 25.5 ± 2.7 0.943
Mode of delivery (spontaneous, OVD, c-section; %) 66.2/8.1/25.8 70.1/5.2/24.7 0.387
Child sex, male/female, % 52.3/47.7 49.8/50.2 0.522
Apgar score at 5 min 9.3 ± 1.0 9.2 ± 1.1 0.084
Apgar score at 10 min 9.6 ± 0.7 9.5 ± 0.8 0.011
Maternal HbA1c, m 43 ± 7.7 45 ± 8.7 0.257
Data are given as mean ± SD or percentage
aComparison between “Quintiles 1–4” and “Quintile 5”
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of the mother. GDM was the strongest predictor of glo-
bal placental DNA methylation (B = 0.215; 95 % CI
0.087–0.342; p = 0.001; Table 4) in this model. Add-
itionally, the maternal smoking status before pregnancy
was also significantly associated with global placental
DNA methylation (B = −0.064; 95 % CI −0.126−0.002;
p = 0.044; Table 4). Ethnicity of the mother, sex of the
child, and maternal age showed no association with
global placental DNA methylation (Table 4).
Discussion
The current study showed in a normally constituted co-
hort of delivering woman that there is a significant posi-
tive correlation between the degree of placental DNA
methylation and GDM, i.e., higher levels of placental
5mC are associated with a higher frequency of GDM.
Analyzing the mean levels of placental 5mC according
to the presence or absence of GDM showed significantly
higher mean values in GDM mothers. For a better un-
derstanding of the relationship between methylation and
the risk for GDM, mothers were ranked in quintiles ac-
cording to the degree of placental DNA methylation.
This revealed a significantly elevated frequency of GDM
in the fifth quintile. Calculating different bivariate logis-
tic regression models with placental DNA methylation
as continuous and categorical variable, adjusted for
known risk factors of GDM, underlined an independent
association between placental DNA hypermethylation
and GDM. An ANCOVA model adjusted for known fac-
tors influencing DNA methylation further substantiated
the independent association between global placental
DNA hypermethylation and GDM.
One limitation of the current study is that no large
data sets of continuous variables describing GDM were
available, only categorical variables displaying the final
diagnosis. Yet, measured term HbA1c concentrations in
Table 3 Model A: logistic regression investigating an association between placental DNA methylation and GDM; model B: logistic
regression investigating an association between placental DNA methylation grouped into the fifth quintile (n = 206) versus quintiles
1–4 (n = 824) and GDM
Model A
Constant −8.647 ± 1.589; p < 0.0001
B S.E. Sig. Exp(B) 95 % CI for Exp(B)
Lower Upper
Maternal age, years 0.061 0.026 0.017 1.063 1.011 1.118
BMI beginning of pregnancy, kg/m2 0.067 0.025 0.008 1.069 1.018 1.124
S/p 2 or more miscarriages, % −0.128 0.502 0.798 0.880 0.329 2.351
Ethnicity (Caucasian, other) −0.111 0.558 0.842 0.895 0.300 2.669
Diabetes in family (yes/no) −0.318 0.289 0.271 0.728 0.413 1.281
Placental DNA methylation, % 0.879 0.267 0.001 2.408 1.427 4.063
Model B
Constant −5.240 ± 1.275; p < 0.0001
B S.E. Sig. Exp(B) 95 % CI for Exp(B)
Lower Upper
Maternal age, years 0.061 0.026 0.017 1.063 1.011 1.118
BMI beginning of pregnancy, kg/m2 0.073 0.025 0.004 1.076 1.024 1.13
S/p 2 or more miscarriages, (%) −0.143 0.501 0.775 0.867 0.325 2.314
Ethnicity (Caucasian, other) −0.139 0.554 0.802 0.87 0.294 2.579
Diabetes in family (yes/no) −0.314 0.289 0.277 0.731 0.415 1.286
Placental DNA methylation (grouped) 1.098 0.292 0.0002 2.999 1.691 5.316
Table 4 ANCOVA analysis of the interaction between factors known to influence global DNA methylation, GDM, and global
placental DNA methylation
Dependent variable: DNA
methylation; r2 = 0.016
B S.E. Power Sig. 95 % CI for B
Lower Upper
Intercept 3.06 0.091 1.000 <0.0001 2.881 3.239
GDM (yes/no) 0.215 0.065 0.911 0.001 0.087 0.342
Smoking before pregnancy (yes/no) −0.064 0.032 0.521 0.044 −0.126 −0.002
Ethnicity (Caucasian, other) 0.112 0.061 0.457 0.064 −0.007 0.231
Sex of the child (male/female) −0.032 0.03 0.191 0.279 −0.09 0.026
Maternal age, years 0.000 0.003 0.05 0.955 −0.005 0.005
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a subset of mothers (n = 94), which were significantly el-
evated in GDM mothers, reinforced a correct diagnosis
of GDM. Another limitation of this study is the usage of
placental tissue without focusing on a specific placental
cell type. Given the large sample size (>1000 placenta
samples), purification of specific placental cell types was
not feasible. However, it was shown by MethylC-seq
analysis that global methylation in whole rhesus placen-
tal tissue was almost identical compared to isolated rhe-
sus trophoblast cell methylation with a correlation of
0.89 [21]. Next to the mentioned limitations, this study
exhibits several strengths. To the best of our knowledge,
it is by now the largest study of its kind analyzing pla-
cental DNA methylation and clinical readouts in 1030
mothers. Moreover, it is the first study that uses a robust
quantitative assessment of placental global DNA methy-
lation, employing the current gold standard LC-MS/MS
[24]. All other studies investigating placental DNA methy-
lation so far were either small, employed only semiquanti-
tative methods of measuring global DNA methylation, or
were focused on specific DNA methylation [9–12, 27].
Given the absence of studies with a comparable study de-
sign in regard to sample size, analyzed tissue, and the
method of global DNA methylation assessment, interpret-
ation of the results of the current study in context with
available literature warrants caution.
Average levels of global placental DNA methylation
were 3.00 ± 0.46 % in uncomplicated pregnancies. This is
in agreement with another study analyzing global pla-
cental DNA methylation using HPLC, also demonstrating
global DNA hypomethylation in comparison to average
global DNA methylation levels observed in somatic
tissues [28].
The current study demonstrated a positive association
between GDM and global placental DNA methylation.
Notwithstanding, a previous preliminary study by Nomura
et al. showed a negative association between global pla-
cental DNA methylation and GDM [9]. However, as only
50 placenta samples were analyzed for global DNA methy-
lation, the observed difference in results is most likely at-
tributable to the ~20-fold smaller study size. Additionally,
the seminquantitative luminometric methylation assay
was used for the measurement of global DNA methyla-
tion, which was shown to be outperformed by other
approaches of global DNA methylation assessment, espe-
cially regarding inter-assay comparability [9, 24, 29].
Two studies, investigating placental DNA methylation
in GDM using the Illumina Infinium 450K BeadChips
array, found a predominance of hypermethylation at
methylation variable positions in GDM exposed placen-
tal samples [11, 12]. However, such arrays only cover
about ~1.5 % of all genomic CpGs [14]. Therefore, the
results of these studies have limited value in discussing
the current observations [14].
Several clinical studies, investigating global DNA
methylation in type 2 diabetes showed higher levels of
global DNA methylation in different types of peripheral
blood cells of diabetic patients [30–36]. Global methylation
in these studies was assessed by LC/MS-MS [30, 33–35] or
LC/MS-MS validated methods [31] or by measuring surro-
gate parameters of global DNA methylation like LINE-1 or
Alu elements [32, 36]. The analysis of global DNA methy-
lation in leukocytes is a well used method in epidemiologic
studies to display associations between global DNA methy-
lation and disease [35, 37, 38]. However, whether changes
in global leukocyte DNA methylation associated with an
insult (e.g., diabetes) also reflect aligned methylation
changes in other tissues remains elusive. Nevertheless, a
general hypothesis raised by Zhao et al., speculating that a
putative link between global DNA hypermethylation and
diabetes could be genomic instability, might also apply for
findings of the current study [32]. The hypothesis is sup-
ported by findings of other studies [39–41], and there is
ample amount of evidence that genomic instability is not
only a hallmark of cancer but also associated with insulin
resistance [42–44]. An underlying factor bearing implica-
tions for both genomic instability and DNA hypermethyla-
tion might be oxidative stress. Literature suggests that
oxidative stress is involved in the development of meta-
bolic diseases [45]. Diabetes itself is associated with in-
creased oxidative stress, and it is well described that
oxidative stress can induce DNA damage, another import-
ant factor in the development of diabetes [43, 45–47]. It
was also shown that reactive oxygen species regulate the
activity of DNA methyltransferases and catalyze the methy-
lation of DNA [48, 49]. Moreover, it was demonstrated in
animal models that an upregulation of the activity or the
expression of DNA methyltransferases is observed in
different types of diabetes [48, 50, 51]. Data from these
recent animal experiments support a positive association
between a diabetic metabolic state and global DNA methy-
lation and additionally delineated putative mechanisms,
connecting diabetes, oxidative stress, and global DNA
hypermethylation [50, 51]. Zhong et al. have shown in a
streptozotocin animal model of gestational diabetes that
maternal diabetes induces an increased expression of
DNA methyltransferases, increased DNA methyltrans-
ferase activity, and increased global DNA methylation
(measured by MethylFlash Methylated DNA Quantification
Kit which analyzes global 5mC content) in E8.75 embryos.
Notably, treatment with the polyphenol epigallocatechin
gallate, which was shown to exert anti-oxidative effects and
to inhibit DNA methyltransferase activity, abrogated these
changes [51–53].
Conclusions
In summary, this study provides the first large scale evi-
dence that placental global DNA hypermethylation is
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associated with GDM independent of established risk
factors. The results of the study are in agreement with
other studies; however, many of the comparable studies
investigated DNA methylation in type 2 diabetes, in
other organs than the placenta or by different methods
of global DNA methylation assessment. Nevertheless,
there is substantial evidence in literature from both
clinical and preclinical experimental studies supporting
an association between a diabetic metabolic state and
global DNA hypermethylation. The results of the current
study have to be confirmed using comparable methods,
to substantiate our understanding of global DNA methyla-
tion involvement in disease. In general, a harmonization
of applied methodology for the measurement of global
DNA methylation is warranted. Differently designed stud-
ies will be needed to demonstrate a causal relationship be-
tween global DNA hypermethylation and GDM and to
elucidate the still very elusive question whether aberrant
global DNA methylation is involved in the pathogenesis of
GDM or a consequence of this disease.
Methods
Ethics, consent, and permissions
The study was approved by the ethics committee of the
university hospital Charité, Berlin, Germany. All clinical
investigations were conducted according to the princi-
ples expressed in the Declaration of Helsinki. Written,
informed consent was obtained from all partaking
mothers prior to data collection.
Clinical study
This observational all-comers study included 1063
mothers delivering at the obstetrics department of
Campus Charité Mitte, Berlin, Germany. Structured inter-
views were performed with the partaking mothers. Eleven
mothers with overt diabetes before pregnancy, nine cases
of preeclampsia, and 13 cases with incomplete data of the
most important variables and confounders were excluded
from the statistical analyses. Given a potential overlap
regarding pathophysiological processes leading to pre-
eclampsia and GDM and the low sample number of
preeclamptic placentas in the current study, it stood to
reason to exclude mother with preeclampsia [9, 54]. In
total, 1030 mothers were included into the statistical ana-
lyses. The majority of mothers (n = 963; 93.5 %) were of
Caucasian ethnicity, while 67 mothers (6.5 %) had other
ethnic backgrounds. Data from the “Mutterpass” docu-
menting the results of follow ups during pregnancy were
also collected. The following data were available for the
dataset: age, ethnicity, body height, body mass index
(BMI) at the beginning of pregnancy, body mass index
(BMI) at the third trimester of pregnancy, parity, diabetes
mellitus before or during pregnancy, family history of dia-
betes, incidence of hypertension before and during
pregnancy, smoking before and during pregnancy, systolic
and diastolic blood pressure measurements recorded
during pregnancy, and in a small subset (n = 94) of
mothers, maternal HbA1c levels at term. GDM was
screened and assessed in all mothers according to the
practice guideline of the German Diabetes Association
(DGG) and the German Association for Gynaecology and
Obstetrics (DGGG) [55]. Biometric data of the newborn
were collected during the routine postnatal examination.
Gestational age at delivery was based on the last men-
strual period, anamnestically assessed during the first
pregnancy examination. The following data of the new-
born were added to the database: birth weight, birth
length, head circumference, child sex, Apgar score 5 min
postnatally and Apgar score 10 min postnatally. A stan-
dardized placenta sample—1 complete cotyledon (cross
section of all layers) from similar locations—was collected
and immediately frozen and stored at −20 °C. For the ex-
traction of DNA a sample of chorionic villi was obtained
from the whole cotyledon.
Data were analyzed using SPSS version 20.0 (SPSS, Inc,
Chicago, IL, USA). Depending on normal distribution,
unpaired t test or Mann-Whitney U test was used when
comparing mean values of two groups. For the compari-
son of categorical variable distribution, chi-square test was
used. Bivariate logistic regression was used to analyze the
relationship of continuous and categorical data with a cat-
egorical outcome, to confirm relevant confounding vari-
ables that had an independent influence, and to adjust for
these in different statistical models. To calculate associa-
tions between a continuous dependent variable and both
categorical and continuous independent variables,
ANCOVA models were used. Bar graphs were calculated
and compiled with Graphpad Prism 5 (GraphPad Software
Inc., La Jolla, California, USA). Probability values <0.05
were considered significant. The authors had full access to
the data and take full responsibility for its integrity.
Analysis of DNA methylation
DNA was extracted using a QIAamp DNA Mini Kit
from Qiagen (Hilden, Germany) together with a RNase
A digestion according to the manufacturer’s protocol.
The concentration and quality of the RNA-free DNA so-
lution were determined by a NanoDrop ND-1000 spec-
trophotometer. DNA hydrolysis was carried out using
DNA Degradase Plus from Zymo Research (Freiburg,
Germany). Briefly, 1 μg of genomic DNA was mixed
with 2.5 μL 10× DNA Degradase Reaction Buffer, and
1 μL DNA Degradase Plus and filled up with water to a
volume of 25 μL. DNA hydrolysis was stopped after 4 h
at 37 °C by adding 75 μL of 0.1 % formic acid. Agarose
gel electrophoresis using 200 ng of the digested DNA
was employed in order to control the completeness of
digestion. Seventy microliters of the hydrolised DNA
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samples were further diluted with 280 μL 0.1 % formic
acid to yield a final concentration of 2 ng digested
DNA/μL. DNA methylation was assessed by liquid
chromatography-electrospray ionization/multi-stage mass
spectrometry (LC-ESI/MS/MS) technique as described
previously [56]. LC-ESI/MS/MS was performed with an
Agilent 1200 series HPLC system connected to an Agilent
6530 Accurate-Mass Q-TOF instrument with Jet Stream-
Interface (Waldbronn, Germany). For chromatographic
separation a Waters (Milford, MA) X-BridgeTM C18
4.6 mm× 150 mm (3.5-μm particle size) protected by a
Waters X-BridgeTM C18 4.6 mm× 20 mm guard column
(5-μm particle size) was used. 0.1 % formic acid in water
(solvent A) and 0.1 % formic acid in methanol (solvent B)
were chosen as mobile phases. The linear gradient elution
was 4–20 % of solvent B in 10 min at a constant flow rate
of 0.5 mL/min. Fifty microliters of the diluted DNA hy-
drolysis samples, typically containing 100-ng digested
DNA, were injected. The optimized ESI-MS/MS pa-
rameters in the positive ion mode were as follows: gas
temperature, 250 °C; drying gas flow, 8 L/min; nebulizer
pressure, 60 psig; sheat gas temperature, 300 °C; capillary
voltage 4000 V; and collision energy 7 V for dC, 13 V for
5mdC, and 10 V for dG. Quantification was accomplished
in selected reaction monitoring (SRM) mode by monitor-
ing a transition pair of m/z 228.0979/112..0505 for dC, m/z
242..1135/126.0662 for 5mdC, and m/z 268.1040/152.0780
for dG, which was used as an internal standard for the
measurement. The scan time was 333 ms for each pair.
The deoxyribonucleosides 2′-deoxyguanosine (dG) mono-
hydrate, 5-methyl-2′-deoxycytidine (5mdC) and 2′-deoxy-
cytidine (dC) were purchased from ABCR (Karlsruhe,
Germany). Hering sperm DNA was obtained from Sigma-
Aldrich (Hamburg, Germany). Nuclease-free water used
for DNA extraction was purchased from Roth (Karlsruhe,
Germany). LC-MS-grade water, methanol, and formic acid
were purchased from VWR international, Inc. (Dresden,
Germany). The global level of DNA methylation was
calculated as the percentage of DNA methylation as
follows: DNA methylation % = 5-methyl-2′-deoxycyti-
dine (5mdC)/[5-methyl-2′-deoxycytidine (5mdC) + 2′-
deoxycytidine (dC)] × 100 %.
Abbreviations
5mC, 5-methylcytosine; AGA, appropriate for gestational age; DGG German
Diabetes Association; DGGG German Association for Gynaecology and
Obstetrics; GDM, gestational diabetes mellitus; IADPSG, International
Association of Diabetes in Pregnancy Study Group; LC-MS/MS, Liquid
chromatography tandem mass spectrometry; LGA, large for gestational
age; OVD, operative vaginal delivery; SGA, small for gestational age
Acknowledgements
Not applicable.
Funding
This study was partially funded by the Deutsche Forschungsgemeinschaft
(DFG grant No. Ho1665/5-2 to Prof. Hocher).
Availability of data and materials
The dataset contains indirect identifiers. As there is some risk of
identification, the dataset was not approved for publication in a freely
accessible manner by the local ethics committee.
Authors’ contributions
BH was responsible for the clinical study design. TP, TS, and BH conducted
the clinical study, edited the manuscript, and contributed to the discussion.
SEDP and CN performed the measurements of global DNA methylation and
edited the manuscript. SEDP contributed to the discussion. CR wrote the
manuscript and analyzed the data. BK coordinated the measurement of
global DNA, edited the manuscript, and contributed to the discussion. BH is
the guarantor of this work and had full access to all the data in the study
and takes responsibility for the integrity of the data and the accuracy of the
data analysis. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was approved by the institutional ethics committee of the
university hospital Charité, Berlin, Germany. All clinical investigations were
conducted according to the principles expressed in the Declaration of
Helsinki. Written, informed consent was obtained from all partaking mothers
prior to data collection.
Author details
1Department of Experimental Nutritional Medicine, Institute of Nutritional
Science, University of Potsdam, Arthur-Scheunert-Allee 114-116, Nuthetal,
Potsdam 14558, Germany. 2Department of Toxicology, Institute of Nutritional
Science, University of Potsdam, Nuthetal, Germany. 3Department of
Nephrology, Campus Charité Mitte, University Hospital Charité, Berlin,
Germany. 4Center for Cardiovascular Research (CCR), Campus Charité Mitte,
University Hospital Charité, Berlin, Germany. 5Faculty of Biotechnology,
University of Surabaya, Surabaya, Indonesia. 6Diaverum Deutschland,
Potsdam, Germany. 7Institut für Laboratoriumsmedizin, Berlin, Germany.
8Department of Basic Medicine, Medical College of Hunan Normal University,
Changsha, China.
Received: 26 April 2016 Accepted: 11 July 2016
References
1. Lappas M, Hiden U, Desoye G, Froehlich J, Hauguel-de Mouzon S,
Jawerbaum A. The role of oxidative stress in the pathophysiology of
gestational diabetes mellitus. Antioxid Redox Signal. 2011;15:3061–100.
2. Schneider S, Bock C, Wetzel M, Maul H, Loerbroks A. The prevalence of
gestational diabetes in advanced economies. J Perinat Med. 2012;40:511–20.
3. Coustan DR. Gestational diabetes mellitus. Clin Chem. 2013;59:1310–21.
4. Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Aktary WM, et al.
Screening and diagnosing gestational diabetes mellitus. Evidence Report/
Technology Assessment no. 210. AHRQ Publication no. 12(13)-E021-EF.
Rockville, MD: Agency for Healthcare Research and Quality; 2012.
5. Gauster M, Desoye G, Tötsch M, Hiden U. The placenta and gestational
diabetes mellitus. Curr Diab Rep. 2012;12:16–23.
6. Reece EA, Leguizamón G, Wiznitzer A. Gestational diabetes: the need for
a common ground. Lancet. 2009;373:1789–97.
7. Schaefer-Graf P-DD med UM, Kautzky-Willer U-PD med A. Diabetes mellitus
und Schwangerschaft. In: Schneider PD med H, Husslein U-PD med P-W,
Schneider U-PD med KTM, editors. Die Geburtshilfe. Berlin: Springer;
2011. p. 435–56.
8. Gabbay-Benziv R, Baschat AA. Gestational diabetes as one of the “great
obstetrical syndromes”—the maternal, placental, and fetal dialog. Best Pract
Res Clin Obstet Gynaecol. 2015;29:150–5.
9. Nomura Y, Lambertini L, Rialdi A, Lee M, Mystal EY, Grabie M, et al. Global
methylation in the placenta and umbilical cord blood from pregnancies with
maternal gestational diabetes, preeclampsia, and obesity. Reprod Sci. 2014;21:131–7.
Reichetzeder et al. Clinical Epigenetics  (2016) 8:82 Page 9 of 10
10. Bouchard L, Hivert M-F, Guay S-P, St-Pierre J, Perron P, Brisson D. Placental
adiponectin gene DNA methylation levels are associated with mothers’
blood glucose concentration. Diabetes. 2012;61:1272–80.
11. Ruchat S-M, Houde A-A, Voisin G, St-Pierre J, Perron P, Baillargeon J-P, et al.
Gestational diabetes mellitus epigenetically affects genes predominantly
involved in metabolic diseases. Epigenetics. 2013;8:935–43.
12. Finer S, Mathews C, Lowe R, Smart M, Hillman S, Foo L, et al. Maternal
gestational diabetes is associated with genome-wide DNA methylation
variation in placenta and cord blood of exposed offspring. Hum Mol Genet.
2015;24(11):3021–9.
13. Binder AM, LaRocca J, Lesseur C, Marsit CJ, Michels KB. Epigenome-wide and
transcriptome-wide analyses reveal gestational diabetes is associated with
alterations in the human leukocyte antigen complex. Clin Epigenetics. 2015;7:79.
14. Busche S, Shao X, Caron M, Kwan T, Allum F, Cheung WA, et al. Population
whole-genome bisulfite sequencing across two tissues highlights the
environment as the principal source of human methylome variation.
Genome Biol. 2015;16:290.
15. Patrushev LI, Kovalenko TF. Functions of noncoding sequences in
mammalian genomes. Biochemistry (Mosc). 2014;79:1442–69.
16. Gregory TR. Synergy between sequence and size in large-scale genomics.
Nat Rev Genet. 2005;6:699–708.
17. Gelfman S, Cohen N, Yearim A, Ast G. DNA-methylation effect on
cotranscriptional splicing is dependent on GC architecture of the exon–
intron structure. Genome Res. 2013;23:789–99.
18. Lev Maor G, Yearim A, Ast G. The alternative role of DNA methylation in
splicing regulation. Trends Genet. 2015;31:274–80.
19. Reddington JP, Pennings S, Meehan RR. Non-canonical functions of the
DNA methylome in gene regulation. Biochem J. 2013;451:13–23.
20. Kurdyukov S, Bullock M. DNA methylation analysis: choosing the right
method. Biology (Basel) [Internet]. 2016 [cited 2016 Jun 11];5. Available
from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810160/
21. Schroeder DI, Jayashankar K, Douglas KC, Thirkill TL, York D, Dickinson PJ, et al.
Early developmental and evolutionary origins of gene body DNA methylation
patterns in mammalian placentas. PLoS Genet. 2015;11, e1005442.
22. Chatterjee A, Macaulay EC, Rodger EJ, Stockwell PA, Parry MF, Roberts HE,
Slatter TL, Hung NA, Devenish CJ, Morison IM. Placental Hypomethylation Is
More Pronounced in Genomic Loci Devoid of Retroelements. G3 (Bethesda).
2016;6(7):1911–21. doi:10.1534/g3.116.030379.
23. Bianco-Miotto T, Mayne BT, Buckberry S, Breen J, Lopez CMR, Roberts CT.
Recent progress towards understanding the role of DNA methylation in
human placental development. Reproduction. 2016;152:R23–30.
24. Liu J, Hesson LB, Ward RL. Liquid Chromatography Tandem Mass
Spectrometry for the Measurement of Global DNA Methylation and
Hydroxymethylation. Journal of Proteomics & Bioinformatics [Internet].
Available from: http://www.omicsonline.org/proteomics-bioinformatics-
abstract.php?abstract_id=15772
25. Tajuddin SM, Amaral AFS, Fernandez AF, Rodriguez-Rodero S, Rodriguez RM,
Moore LE, et al. Genetic and non-genetic predictors of LINE-1 methylation
in leukocyte DNA. Environ Health Perspect. 2013;121:650–6.
26. Boeke CE, Baccarelli A, Kleinman KP, Burris HH, Litonjua AA, Rifas-Shiman SL,
et al. Gestational intake of methyl donors and global LINE-1 DNA
methylation in maternal and cord blood: prospective results from a folate-
replete population. Epigenetics. 2012;7:253–60.
27. Lesseur C, Armstrong DA, Paquette AG, Li Z, Padbury JF, Marsit CJ. Maternal
obesity and gestational diabetes are associated with placental leptin DNA
methylation. Am J Obstet Gynecol. 2014;211(6):654.e1-9.
28. Fuke C, Shimabukuro M, Petronis A, Sugimoto J, Oda T, Miura K, et al. Age
related changes in 5-methylcytosine content in human peripheral leukocytes
and placentas: an HPLC-based study. Ann Hum Genet. 2004;68:196–204.
29. Lisanti S, Omar WAW, Tomaszewski B, De Prins S, Jacobs G, Koppen G, et al.
Comparison of methods for quantification of global DNA methylation in
human cells and tissues. PLoS One. 2013;8.
30. Maghbooli Z, Larijani B, Emamgholipour S, Amini M, Keshtkar A, Pasalar P.
Aberrant DNA methylation patterns in diabetic nephropathy. J Diabetes
Metab Disord. 2014;13:69.
31. Simar D, Versteyhe S, Donkin I, Liu J, Hesson L, Nylander V, et al. DNA
methylation is altered in B and NK lymphocytes in obese and type 2
diabetic human. Metab Clin Exp. 2014;63:1188–97.
32. Zhao J, Goldberg J, Bremner JD, Vaccarino V. Global DNA methylation is
associated with insulin resistance: a monozygotic twin study. Diabetes.
2012;61:542–6.
33. Maghbooli Z, Hossein-Nezhad A, Larijani B, Amini M, Keshtkar A. Global DNA
methylation as a possible biomarker for diabetic retinopathy. Diabetes
Metab Res Rev. 2014;31(2):183–9.
34. Maghbooli Z, Hossein-Nezhad A, Larijani B, Pasalar P, Keshtkar AA.
Association between alterations in global DNA methylation and
predisposing factors in diabetes: a high pressure liquid chromatography
based study. Minerva Med. 2015;106:221–31.
35. Maghbooli Z, Hossein-nezhad A, Larijani B, Amini M, Keshtkar A. Global DNA
methylation as a possible biomarker for diabetic retinopathy. Diabetes
Metab Res Rev. 2015;31:183–9.
36. Pearce MS, McConnell JC, Potter C, Barrett LM, Parker L, Mathers JC, et al.
Global LINE-1 DNA methylation is associated with blood glycaemic and
lipid profiles. Int J Epidemiol. 2012;41:210–7.
37. Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM. DNA
methylation in white blood cells: association with risk factors in
epidemiologic studies. Epigenetics. 2011;6:828–37.
38. Kim YO, Li C, Sun BK, Kim JS, Lim SW, Choi BS, et al. Preconditioning with
1,25-dihydroxyvitamin D3 protects against subsequent ischemia-reperfusion
injury in the rat kidney. Nephron Exp Nephrol. 2005;100:e85–94.
39. Walters RJ, Williamson EJ, English DR, Young JP, Rosty C, Clendenning M, et al.
Association between hypermethylation of DNA repetitive elements in white
blood cell DNA and early-onset colorectal cancer. Epigenetics. 2013;8:748–55.
40. Neale RE, Clark PJ, Fawcett J, Fritschi L, Nagler BN, Risch HA, et al.
Association between hypermethylation of DNA repetitive elements in white
blood cell DNA and pancreatic cancer. Cancer Epidemiol. 2014;38:576–82.
41. Liao LM, Brennan P, van Bemmel DM, Zaridze D, Matveev V, Janout V, et al.
LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer.
PLoS One. 2011;6.
42. Moran LJ, Noakes M, Clifton PM, Norman RJ, Fenech MF. Genome instability
is increased in lymphocytes of women with polycystic ovary syndrome and
is correlated with insulin resistance. Mutat Res. 2008;639:55–63.
43. Attia SM, Helal GK, Alhaider AA. Assessment of genomic instability in normal
and diabetic rats treated with metformin. Chem Biol Interact. 2009;180:296–304.
44. Binici DN, Karaman A, Coşkun M, Oğlu AU, Uçar F. Genomic damage in
patients with type-2 diabetes mellitus. Genet Couns. 2013;24:149–56.
45. Rani V, Deep G, Singh RK, Palle K, Yadav UCS. Oxidative stress and metabolic
disorders: pathogenesis and therapeutic strategies. Life Sci. 2016;148:183–93.
46. Milic M, Frustaci A, Del Bufalo A, Sánchez-Alarcón J, Valencia-Quintana R,
Russo P, et al. DNA damage in non-communicable diseases: a clinical and
epidemiological perspective. Mutat Res. 2015;776:118–27.
47. Dong D, Yu J, Wu Y, Fu N, Villela NA, Yang P. Maternal diabetes triggers
DNA damage and DNA damage response in neurulation stage embryos
through oxidative stress. Biochem Biophys Res Commun. 2015;467:407–12.
48. Wei D, Loeken MR. Increased DNA methyltransferase 3b (Dnmt3b)-mediated
CpG island methylation stimulated by oxidative stress inhibits expression of
a gene required for neural tube and neural crest development in diabetic
pregnancy. Diabetes. 2014;63:3512–22.
49. Hai Z, Zuo W. Aberrant DNA methylation in the pathogenesis of
atherosclerosis. Clin Chim Acta. 2016;456:69–74.
50. Williams KT, Schalinske KL. Tissue-specific alterations of methyl group
metabolism with DNA hypermethylation in the Zucker (type 2) diabetic
fatty rat. Diabetes Metab Res Rev. 2012;28:123–31.
51. Zhong J, Xu C, Reece EA, Yang P. The green tea polyphenol EGCG alleviates
maternal diabetes-induced neural tube defects by inhibiting DNA
hypermethylation. Am J Obstet Gynecol. 2016. doi:10.1016/j.ajog.2016.03.009.
52. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea polyphenol
(−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates
methylation-silenced genes in cancer cell lines. Cancer Res. 2003;63:7563–70.
53. Legeay S, Rodier M, Fillon L, Faure S, Clere N. Epigallocatechin gallate: a
review of its beneficial properties to prevent metabolic syndrome. Nutrients.
2015;7:5443–68.
54. Liu L, Zhang X, Rong C, Rui C, Ji H, Qian Y, et al. Distinct DNA methylomes
of human placentas between pre-eclampsia and gestational diabetes
mellitus. Cell Physiol Biochem. 2014;34:1877–89.
55. Kleinwechter H, Schäfer-Graf U, Bührer C, Hoesli I, Kainer F, Kautzky-Willer A,
et al. Gestational diabetes mellitus (GDM) diagnosis, therapy and follow-up
care. Exp Clin Endocrinol Diabetes. 2014;122:395–405.
56. Dwi Putra SE, Neuber C, Reichetzeder C, Hocher B, Kleuser B. Analysis of
genomic DNA methylation levels in human placenta using liquid
chromatography-electrospray ionization tandem mass spectrometry. Cell
Physiol Biochem. 2014;33:945–52.
Reichetzeder et al. Clinical Epigenetics  (2016) 8:82 Page 10 of 10
